Transcriptome Study of Acute Myocardial Infarction

Screening Pathogenic Genes Associated With Acute Myocardial Infarction and Studying Its Relevant Molecular Mechanism

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03158597

Enrollment

Registered

2017-05-18

Start date

2017-06-01

Completion date

2019-12-31

Last updated

2017-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Infarction

Brief summary

This study aims to compare whole-blood microarray gene-expression profiling between patients with acute myocardial infarction and normal participants without cardiovascular diseases. Firstly, screening differentially genes of mRNA to perform gene ontology and pathway analysis. Secondly, predicting target genes regulated by microRNA and constructing coexpression network with mRNA. Thirdly, biological function experiment of microRNA. Finally, revealing pathogenic mechanisms associated with acute myocardial infarction.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

MALE

Age

20 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* AMI patients: 1. 20-50 years of age 2. Symptoms of ischaemia 3. New significant ST-segment-T wave changes in ECG and definitive diagnosis of non-ST elevation MI or ST elevation MI 4. Cardiac troponin with at least one value above the 99th percentile upper reference limit * Normal control participants: 1. 20-50 years of age 2. Normal ECG 3. BMI \<24kg/m2 4. systolic blood pressure \<140mmHg 5. diastolic blood pressure \<90mmHg 6. Total cholesterol \<200mg/dl (5.18mmol/L) 7. Triglyceride \<150mg/dl (1.70mmol/L) 8. High density lipoprotein cholesterol \>=40mg/dl (1.04mmol/L) 9. Low density lipoprotein cholesterol \<130mg/dl (3.37mmol/L) 10. Fasting blood glucose \<100mg/dl (5.6mmol/L) 11. Not taking antihypertensive or hypolipidemic or hypoglycemic drugs

Exclusion criteria

1. Cardiac death with symptoms suggestive of myocardial ischaemia and presumed new ischaemic ECG changes, but death occurred before cardiac biomarkers were obtained, or before cardiac biomarker values would be increased 2. Prior myocardial infarction 3. Percutaneous coronary intervention related MI 4. Stent thrombosis associated with MI 5. Coronary artery bypass grafting related MI 6. Recurrent MI or reinfarction 7. Myocardial injury with necrosis caused by transcatheter aortic valve implantation or mitral clip or ablation of arrhythmias 8. Myocardial injury or infarction associated with heart failure 9. Myocardial infarction in the intensive care unit 10. Other diseases: previous history of ASCVD, cancer, rheumatoid arthritis, liver or kidney disease, myeloproliferative disorders, chronic inflammation, peripheral vascular disease 11. Not available informed consent

Design outcomes

Primary

Measure	Time frame
Number of screening differentially expressed genes associated with acute myocardial infarction as measured by microarray	up to 3 years

Countries

China

Outcome results